Drug Trial Radar · NCT03813199
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Feb 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Jul 4, 2019
Primary completion
Apr 27, 2021
Study completion Apr 27, 2021
Sponsor
- Lead sponsor
- Abivax S.A.Industry
- Sponsor type
- Industry
- First posted
- Jan 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase IIa study aims at investigating the safety and tolerability of 2 dose-levels of ABX464 administered daily in combination with methotrexate (MTX) in patients with moderate to severe active Rheumatoid Arthritis (RA) who had an inadequate response to MTX or/and to one or more anti- tumor necrosis factor alpha (TNFα) therapies.
Conditions
- Rheumatoid Arthritis
Interventions
ABX464 50mgDrug
ABX464 is a new anti-inflammatory drug
Matching PlaceboDrug
placebo matching with ABX464
ABX464 100mgDrug
ABX464 is a new anti-inflammatory drug
MethotrexateDrug
MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Treatment-emergent Adverse Events in the ABX464 Treated Patients Versus PlaceboTime frame: through study completion, an average of 15 weeks
Locations
24 sites in 5 countries. Site status is shown where the registry gives one.
Cliniques Universitaires Saint-Luc
Brussels, Belgium
UZ Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
ZNA Jan Palfijn
Merksem, Belgium
Fakultni Tomayerova nemocnice
Prague, Czechia
Revmatologicky ustav
Prague, Czechia
CHU de Brest - Hôpital Cavale Blanche
Brest, France
CHD Vendée
La Roche-sur-Yon, France
CHU de Montpellier - Lapeyronie
Montpellier, France
GHR Mulhouse Sud-Alsace
Mulhouse, France
CHU de Nice - Hôpital Pasteur
Nice, France
CHR d'Orléans
Orléans, France
APHP - Hôpital Salpétrière
Paris, France
CHU de Tours - Hôpital Trousseau
Tours, France
Complex Medical Centre - Déli Klinika
Budapest, Hungary
CRU Hungary Ltd.
Miskolc, Hungary
CMed Rehabilitációs és Diagnosztikai Központ
Székesfehérvár, Hungary
ClinicMed Daniluk, Nowak Sp. J.
Bialystok, Poland
Pratia MCM
Krakow, Poland
Zespół Poradni Specjalistycznych REUMED
Lublin, Poland
NZOZ Lecznica MAK-MED S.C.
Nadarzyn, Poland
Medyczne Centrum Hetmańska
Poznan, Poland
National Institute of Geriatrics
Warsaw, Poland
RHEUMA MEDICUS Zakład Opieki Zdrowotnej
Warsaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.